New Delhi: The Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, Government of India, successfully hosted the 7th India-Japan Medical Product Regulatory Symposium at the FICCI Convention Hall. This event, part of the ongoing collaboration between India and Japan, is in line with the Memorandum of Cooperation (MoC) signed to foster joint efforts in medical product regulations.
Approximately 200 delegates attended the symposium, including representatives from the Ministry of Health & Family Welfare, India, and the Ministry of Health, Labour and Welfare (MHLW), Japan. Regulatory authorities from CDSCO, India, and the Pharmaceuticals and Medical Devices Agency (PMDA), Japan, along with industry leaders from the pharmaceutical, medical devices, and biologicals-biosimilar sectors, participated in the event.
The MoC, signed in December 2015, underscores mutual cooperation in medical product regulations and is set to continue until December 2025. These symposiums are alternately hosted in India and Japan, serving as essential platforms for exchanging insights and enhancing regulatory practices.
The symposium featured insightful presentations by Indian and Japanese drug regulatory authorities, followed by in-depth discussions on emerging topics in pharma, medical devices, and regenerative medicines. These deliberations were pivotal in updating industry stakeholders on the latest regulatory initiatives in both countries.
The inaugural session was graced by esteemed dignitaries including Rajiv Wadhawan, Joint Secretary, MoHFW; Dr. Rajeev Singh Raghuvanshi, DCGI, CDSCO; Yada Shinji, Executive Director, PMDA; Dr. Hirota Mitsue, Deputy Director, MHLW; and Dr. Ranga Chandrashekar, JDCI, CDSCO. The event garnered participation from 80 drug regulators and 120 industry representatives from India and Japan, facilitating fruitful exchanges on regulatory updates and best practices.
The symposium underscored the commitment of both nations to enhance cooperation in the field of medical product regulations, aiming to ensure the safety, efficacy, and quality of medical products available in both countries. This collaborative effort is expected to pave the way for more streamlined regulatory processes and foster innovation in the medical products sector.